Updates on Peritoneal Surface Malignancy Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy Morbidity and Mortality Outcomes from the Shiraz Surgical Oncology Group

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are well-known in the treatment of different types of peritoneal carcinomatosis (PC). CRS and HIPEC are associated with several major comorbidity and can affect patients short-term and long-term outcomes. The present study aimed to evaluate the short term follow up, mortality and morbidity rate of CRS and HIPEC of recent period surgery compared with our previously reported study patients.Method: Short-term follow-up data were collected and analyzed for 150 PC patients who underwent CRS-HIPEC between 2017 and 2021 compared with 43 patients from our retrospective cohort study. Data were analyzed using SPSS 23. The statistical significance was determined by a P-value < 0.05.Results: Mortality at 60 days of the 2017-2021 group and the 2016 group was 1.33% (2/150) and 7 % (3/43), respectively. The 2017-2021 group showed less minor and major complications according to Clavien-Dindo classification. Overall, the mortality and morbidity rates were lower as compared with our previous reported study.Conclusion: Our center has achieved an acceptable and progressive route through the use of CRS and HIPEC for PC, as demonstrated by our study.